Risk factors of endometrial cancer in patients with endometrial hyperplasia: implication for clinical treatments

Jie Zhao¹, Yongting Hu¹, Yanan Zhao², Dongmei Chen², Tingfeng Fang² and Miao Ding²*

Abstract
Background: Endometrial hyperplasia (EH) is commonly-seen in the patients with endometrial cancer (EC), we aimed to evaluated the risk factors of EC in patients with EH, to provide evidence to the clinical prevention and treatment of EC.

Methods: This study was a retrospective study design. EH patients confirmed by pathological examinations and treated with hysterectomy in our hospital from June 1, 2018 to February 28, 2021 were included. The clinical characteristics of EC and no-EC patients were compared and analyzed. Logistics regression analyses were conducted to evaluate the risk factors of EC in patients with EH.

Results: A total of 228 EH patients were included, the incidence of EC in the EH patients was 31.58%. There were significant differences in the age, BMI, diabetes, hypertension and pathology of EH between EC and no EC groups (all \( P < 0.05 \)), no significant differences in the hyperlipidemia, preoperative CA125, number of deliveries, menopause and endometrial thickness between EC and no EC groups were found (all \( P > 0.05 \)). Logistic regression analyses indicated that age > 50 y (OR 3.064, 95% CI 1.945–5.931), BMI \( \geq 25 \) kg/m² (OR 2.705, 95% CI 1.121–3.889), diabetes (OR 3.049, 95% CI 1.781–5.114), hypertension (OR 2.725, 95% CI 1.108–3.431) and severe hyperplasia (OR 3.181, 95% CI 1.496–4.228) were the risk factors of EC in patients with EH (all \( P < 0.05 \)).

Conclusions: The risk of EC in EH patients is high, especially for those patients with age > 50 y, BMI \( \geq 25 \) kg/m², diabetes, hypertension and severe hyperplasia, special attentions should be paid for occurrence of EC and early diagnosis and early treatment are needed for those patients.

Keywords: Endometrial cancer, Endometrial hyperplasia, Gynecology, Treatment, Care, Nursing

Background
Endometrial cancer (EC) is one of the common malignant tumors in gynecology, and its incidence is increasing year by year, and is showing a trend of younger onset age \[1\]. It is generally believed that the continuous stimulation of estrogen without progesterone antagonism leads to endometrial hyperplasia and then cancerous transformation \[2, 3\]. Endometrial hyperplasia (EH) is a common gynecological endocrine disease, which mainly manifests as irregular vaginal bleeding, infertility, and even malignant transformation \[4\]. Endometrial dysplasia has certain tendency to become cancerous, and it is recognized as a precancerous lesion of EC with incidence of 23.15–29.08% \[5, 6\]. Therefore, early detection and intervention of EH is of great significance to improve the prognosis of patients.
Previous studies [7, 8] have shown that it’s very common that EH and EC can coexist in patients. The risk of endometrial dysplasia combined with endometrial cancer is as high as 25.76 to 59.22% [9, 10]. Clinically, there is a certain missed diagnosis rate in the diagnosis of EC [11]. How to identify high-risk patients with EC from patients with EH, is important to guide clinical treatment decisions and improve the prognosis of patients. Therefore, this present study analyzed the clinicopathological data of patients diagnosed with EH before hysterectomy, aimed to explore the high-risk factors of EC in patients with EH, to provide evidence support to the early prevention and clinical treatment of EC.

Methods
Ethics
This study was a retrospective study design. In this study, all methods were conducted in comply with the relevant guidelines and regulations. This present study had been verified and approved by the ethical committee of our hospital (approval number: MD10180068-2c), and written informed consents had been obtained from all the included patients.

Patients
We selected EH patients treated with hysterectomy in our hospital from June 1, 2018 to February 28, 2021 as the study populations. The criterial for patient inclusion were: the endometrial thickness was determined by the B-ultrasound (endometrial thickness ≥ 4 mm) and pathological examinations, the ultrasound examinations of all selected patients were performed by the same group of sonographers in our hospital; patients underwent hysterectomy treatment in our hospital, and there were complete postoperative pathological reports; there was no history of hormone replacement therapy in the past 1 year. All consecutive patients meeting the selection criteria were included. Patients who did not agree to participant in this study and did not sign the inform consents were excluded.

Data collection
We collected personal and treatment information of patients, including age, body mass index (BMI), diabetes, hypertension, hyperlipidemia, preoperative CA125 (U/ml) level, number of deliveries, menopause status, preoperative endometrial thickness, and the final pathological results.

Treatment and follow-up
The diagnosis of EH referred to relevant standards and criteria [12, 13], and EH was divided into mild, moderate, and severe group according to the degree of disease. All patients underwent total hysterectomy in our hospital. According to the final pathological results after total hysterectomy, it was judged whether EC existed at the same time, and the diagnosis of EC referred to relevant standards. If the postoperative pathological examination results suggested that there was EC, further corresponding treatments were conducted. We conducted follow-up till the discharge of patients.

Statistical method
We used SPSS 24.0 software to analyze the data, and the measurement data were expressed as mean ± standard deviation, and the comparison between the two groups used independent sample t test. Categorical variables were expressed as percentages, and Chi-square or Fisher exact probability tests were used for comparison between groups. We used logistic multiple regression analysis to explore high-risk factors related to EC. In this study, the difference was statistically significant with P < 0.05.

Results
Patients
A total of 228 EH patients were included, of whom 72 patients had EC, the incidence of EC in the EH patients was 31.58%. As presented in Table 1, there were significant differences in the age, BMI, diabetes, hypertension and pathology of EH between EC and no EC groups (all P < 0.05), no significant differences in the hyperlipidemia, preoperative CA125, number of deliveries, menopause and endometrial thickness between EC and no EC groups were found (all P > 0.05).

Risk factors of EC in patients with EH
The variable assignments of multivariate logistic regression were presented in Table 2. As indicated in Table 3, logistic regression analyses indicated that age > 50 y (OR 3.064, 95% CI 1.945–5.931), BMI ≥ 25 kg/m² (OR 2.705, 95% CI 1.121–3.889), diabetes (OR 3.049, 95% CI 1.781–5.114), hypertension (OR 2.725, 95% CI 1.108–3.431) and severe hyperplasia (OR 3.181, 95% CI 1.496–4.228) were the risk factors of EC in patients with EH (all P < 0.05).

Discussions
The results of this present study have found that the incidence of EC in the EH patients was 31.58%, which is similar to previous reports [14, 15]. Besides, we have found that for patients with age > 50 y, BMI ≥ 25 kg/m², diabetes, hypertension and severe hyperplasia, they may have higher risks of EC in patients with EH, early targeted interventions are needed for patients with those factors. The increase in estrogen levels in the body caused by various reasons continuously stimulates the proliferation of endometrial tissue [16]. The proliferated
endometrial tissue is stimulated by a single estrogen for a long time without progesterone antagonism, which is likely to cause excessive endometrial cell proliferation [17]. Tumor cells infiltrate local blood vessels or necrosis and disintegration of their own tissues can cause bleeding [18]. The most common pathological type of endometrial cancer is endometrioid adenocarcinoma, which accounts for about 74.25 to 80.11% [19, 20]. Therefore, the early identification and treatment of EC in the EH patients is vital to the prognosis of EH patients.

The main cause is the long-term estrogen exposure of the endometrium and the lack of progesterone antagonism [21]. It is generally believed that endometrial cancer is more likely to occur in perimenopausal women [22]. Studies [23–25] have pointed out that age is a high-risk factor for endometrial dysplasia coexisting with EC. Previous study [26] has reported that endometrial hyperplasia patients aged 40–59 have an increased risk of endometrial cancer (OR 3.07, 95% CI 1.18–7.97); The risk is higher when the age is ≥60 (DR 6.65, 95% CI 1.75–25.3). The potential reasons may be that due to the perimenopausal age at which EC is likely to occur, which is related to the decline of the body’s immune function [27]. It’s been reported that the incidence of EC under the age of 50 is 102 per 100,000, while the incidence of EC over the age of 50 has risen to 1374 per 100,000 [28]. The older the age, the more severe the disease and the lower the survival rate [29]. The results of this study also suggest that age ≥50 years old is a high-risk factor for the development of EC. Therefore, for the elderly, especially those with EH aged ≥48 years, they need to be treated with caution in clinical practice.

The pathological change of EH must be considered in the diseases progress. Among endometrial diseases, EH

### Table 1 The characteristics of included patients

| Variables                  | EC group (n = 72) | No EC group (n = 156) | χ²/t   | P    |
|----------------------------|------------------|----------------------|--------|------|
| Age (y)                    | 54.33 ± 9.26     | 46.12 ± 9.39         | 8.124  | 0.021|
| BMI (kg/m²)                | 27.16 ± 4.54     | 23.11 ± 5.95         | 6.101  | 0.036|
| Diabetes                   | 39 (54.17%)      | 44 (28.21%)          | 1.114  | 0.019|
| Hypertension               | 52 (72.22%)      | 68 (43.59%)          | 1.271  | 0.038|
| Hyperlipidemia             | 17 (23.61%)      | 30 (19.23%)          | 1.855  | 0.076|
| Preoperative CA125 (U/ml)  | 21.69 ± 5.14     | 19.88 ± 4.24         | 1.232  | 0.095|
| Number of deliveries       |                  |                      |        |      |
| 0                          | 8 (11.11%)       | 20 (12.82%)          | 1.140  | 0.011|
| 1                          | 22 (30.56%)      | 48 (30.77%)          |        |      |
| 2                          | 37 (51.39%)      | 77 (49.36%)          |        |      |
| ≥3                         | 5 (6.94%)        | 11 (49.36%)          |        |      |
| Menopause                  | 31 (43.06%)      | 63 (40.38%)          | 3.114  | 0.065|

### Table 2 The variable assignment of multivariate logistic regression

| Factors                    | Variables | Assignment |
|----------------------------|-----------|------------|
| EC                         | Y         | Yes = 1, no = 2 |
| Age (y)                    | X₁        | ≥50 = 1, <50 = 2 |
| BMI (kg/m²)                | X₂        | ≥25 = 1, <25 = 2 |
| Diabetes                   | X₃        | Yes = 1, No = 2 |
| Hypertension               | X₄        | Yes = 1, No = 2 |
| Pathology of EH            | X₅        | Severe hyperplasia = 1, moderate hyperplasia = 2, mild hyperplasia = 3 |

### Table 3 The logistic regression analysis on the risk factors of endometrial cancer in patients with endometrial hyperplasia

| Variables                  | β         | Std. | OR     | 95% CI   | P    |
|----------------------------|-----------|------|--------|----------|------|
| Age > 50 y                 | 0.121     | 0.287| 3.064  | 1.945–5.931| 0.012|
| BMI ≥ 25 kg/m²             | 0.115     | 0.206| 2.705  | 1.121–3.889| 0.027|
| Diabetes                   | 0.106     | 0.152| 3.049  | 1.781–5.114| 0.009|
| Hypertension               | 0.142     | 0.187| 2.725  | 1.108–3.431| 0.034|
| Severe hyperplasia         | 0.119     | 0.105| 3.181  | 1.496–4.228| 0.019|

BMI body mass index, OR odds ratio, CI confidence interval

and disintegration of their own tissues can cause bleeding [18]. The most common pathological type of endometrial cancer is endometrioid adenocarcinoma, which accounts for about 74.25 to 80.11% [19, 20]. Therefore, the early identification and treatment of EC in the EH patients is vital to the prognosis of EH patients.

The main cause is the long-term estrogen exposure of the endometrium and the lack of progesterone antagonism [21]. It is generally believed that endometrial cancer is more likely to occur in perimenopausal women [22]. Studies [23–25] have pointed out that age is a high-risk factor for endometrial dysplasia coexisting with EC. Previous study [26] has reported that endometrial hyperplasia patients aged 40–59 have an increased risk of endometrial cancer (OR 3.07, 95% CI 1.18–7.97); The risk is higher when the age is ≥60 (DR 6.65, 95% CI 1.75–25.3). The potential reasons may be that due to the perimenopausal age at which EC is likely to occur, which is related to the decline of the body’s immune function [27]. It’s been reported that the incidence of EC under the age of 50 is 102 per 100,000, while the incidence of EC over the age of 50 has risen to 1374 per 100,000 [28]. The older the age, the more severe the disease and the lower the survival rate [29]. The results of this study also suggest that age ≥50 years old is a high-risk factor for the development of EC. Therefore, for the elderly, especially those with EH aged ≥48 years, they need to be treated with caution in clinical practice.

The pathological change of EH must be considered in the diseases progress. Among endometrial diseases, EH
is the most common benign disease, and EC is one of the most common female reproductive system tumors, accounting for 20 to 30% of female reproductive tract malignant tumors [30]. In the past 20 years, the incidence of endometrial cancer has shown an obvious upward trend [31]. It is generally believed that endometrial lesions are a process in which the lesions continue to progress, that is, from not accompanied by EH to accompanied by EH, and finally progressing to well-differentiated EC [32, 33]. However, some scholars [21, 34] have reported that the incidence of EC in patients with endometrial hyperplasia is 12.18–46.34%. The results of this study also suggest that severe EH is also a high-risk factor for EC. However, the clinical reason for the failure to find coexisting EC before surgery may be that the preoperative endometrial sampling is mainly by diagnosing curettage, AEH lesions may be single or scattered lesions, which are affected by the experience of the surgeon, and there is a possibility of missed curettage [35, 36]. In addition, the diagnosis of well-differentiated EC is mainly based on the presence or absence of endometrial stroma, but it is sometimes difficult to determine [37]. This study has found that the risk of patients with endometrial cancer increase significantly with the severity of EH. Therefore, for patients whose endometrial biopsy pathology is severe EH, due to the high probability of EC, early alerts of EC are needed for those patients.

Several high-risk factors for EC should be concerned and get the attention of clinical health workers. Studies [38, 39] have pointed out that obesity and diabetes are high-risk factors for EC. For every 5 kg/m² increase in BMI, the risk of EC increases 1.6 times. Several studies [40, 41] have also shown that obesity in patients with endometrial cancer also increases the risk of endometrial cancer-related deaths. The reason is that adipose tissue is the source of estrogen in the body. Obesity causes excessive endogenous estrogen to act on the endometrium, leading to EH and EC. Studies [3, 42, 43] have shown that when the insulin resistance index is greater than or equal to 2.8809, the relative risks of endometrial hyperplasia and endometrial cancer are 35.22 and 30.59, respectively. It’s been found that when BMI ≥ 25 kg/m², progesterone treatment is less effective and prone to recurrence. Therefore, weight control should be strengthened during treatment and follow-up. Simple hypertension does not increase the occurrence of endometrial cancer, but hypertension patients are often complicated by obesity and diabetes. Therefore, early control of weight, blood sugar and blood pressure are vital to improve the prognosis of patients.

It must be noted that the pathological types of EC with coexisting EH are hormone-dependent EC, more than 90% are well-differentiated cancers, about 40% of the lesions are confined to the endometrium, and about 50% are accompanied by superficial muscle layer infiltration, about 10% is accompanied by deep muscle layer infiltration [44]. Besides, there may be some immunohistochemical factors in predicting EC in EH patients. AT-rich interaction domain 1A (ARID1A) loss in premalignant EH is an accurate and almost perfectly specific prognostic marker for coexistent cancer [45]. Besides, it’s been found that PTEN loss in EH is a risk factor for EC, but is not reliable in predicting the risk of EC [46]. In this present study, four cases underwent lymph node resection after surgery, and the pathological examination results were negative. There was no recurrence or death due to cancer in the follow-up. Previous study [47] have found that after resection of the uterus due to EH are highly differentiated stage I cases, with only 6 cases of moderately differentiated cancer and 2 cases of poorly differentiated cancer.

Conclusions
In conclusion, we have found that the incidence of EC in the EH patients was 31.58%, age > 50 y, BMI ≥ 25 kg/m², diabetes, hypertension and severe hyperplasia are the independent risk factors of EC in patients with EH. For controllable high-risk factors, such as obesity, diabetes and hypertension, clinical education and intervention should be strengthened with more focus on changes in patients’ lifestyles, and early preventions are needed to reduce the development of EC.

Abbreviations
EC: Endometrial cancer; EH: Endometrial hyperplasia; BMI: Body mass index; OR: Odds ratio; CI: Confidence interval.

Acknowledgements
None.

Authors’ contributions
JZ, MD designed research; JZ, YH, YZ, DC, TF, MD conducted research; JZ, YH analyzed data; JZ, MD wrote the first draft of manuscript; MD had primary responsibility for final content. All authors read and approved the final manuscript.

Funding
None.

Availability of data and materials
All data generated or analyzed during this study are included in this published article.

Declarations
Ethics approval and consent to participate
In this study, all methods were conducted in comply with the relevant guidelines and regulations. This present study had been verified and approved by the ethical committee of Sun Yat-sen Memorial Hospital of Sun Yat-sen University (approval number: MD10180068-2c), and written informed consents had been obtained from all the included patients.
References

1. Doherty MT, Sanni OB, Coleman HG, Cardwell CR, McCluggage WG, Doherty JA, et al. Preoperative predictors of endometrial cancer at time of hysterectomy for endometrial intraepithelial neoplasia or complex atypical hyperplasia. Am J Obstet Gynecol. 2020;222(1):60.e61–60.e67.

2. Jordan SJ, Na R, Weiderpass E, Adami HO, van den Brandt PA, Nyren O. Premenopausal abnormal uterine bleeding and risk of endometrial cancer: a pooled analysis of individual participant data in the Epidemiology of Endometrial Cancer Consortium. Int J Cancer. 2017;148(9):2068–78.

3. Clarke MA, Long BJ, Sherman ME, Lemens MA, Podratz KC, Hopkins MR, thuận xãńska E, Pacheco-Matembeck O, O'Shaughnessy P, et al. Risk factors for endometrial cancer or hyperplasia in adolescents and women ≥11 mm: a systematic review and meta-analysis. J Clin Ultrasound. 2020;48(9):565–70.

4. Rosen MW, Tasset J, Kobernik EK, Smith EM, Johnston C, Quint EH. Risk factors for endometrial cancer or hyperplasia in adolescents and women 25 years old or younger. J Pediatr Adolesc Gynecol. 2019;32(5):546–9.

5. Pal N, Broaddus RR, Urbaner DL, Balakrishnan N, Milbourne A, Schmeler KM, Meyer LA, Soliman PT, Lu KH, Ramirez PT, et al. Treatment of low-risk endometrial cancer and complex atypical hyperplasia with the levonorgestrel-releasing intrauterine device. Obstet Gynecol. 2018;131(1):109–16.

6. Alcazar JL, Bonilla L, Marucco J, Padilla AI, Chacon E, Manzour N, Salas G, De Placido G, Insabato L, Zullo F. Endometrial hyperplasia and the risk of coexistent cancer: WHO versus EIN criteria. Histopathology. 2019;74(5):676–87.

7. Alcazar JL, Bonilla L, Marucco J, Padilla AI, Chacon E, Manzour N, Salas G, De Placido G, Insabato L, Zullo F. Endometrial hyperplasia and the risk of coexistent cancer: WHO versus EIN criteria. Histopathology. 2019;74(5):676–87.

8. Alcazar JL, Bonilla L, Marucco J, Padilla AI, Chacon E, Manzour N, Salas G, De Placido G, Insabato L, Zullo F. Endometrial hyperplasia and the risk of coexistent cancer: WHO versus EIN criteria. Histopathology. 2019;74(5):676–87.

9. Alcazar JL, Bonilla L, Marucco J, Padilla AI, Chacon E, Manzour N, Salas G, De Placido G, Insabato L, Zullo F. Endometrial hyperplasia and the risk of coexistent cancer: WHO versus EIN criteria. Histopathology. 2019;74(5):676–87.

10. Alcazar JL, Bonilla L, Marucco J, Padilla AI, Chacon E, Manzour N, Salas G, De Placido G, Insabato L, Zullo F. Endometrial hyperplasia and the risk of coexistent cancer: WHO versus EIN criteria. Histopathology. 2019;74(5):676–87.

11. Alcazar JL, Bonilla L, Marucco J, Padilla AI, Chacon E, Manzour N, Salas G, De Placido G, Insabato L, Zullo F. Endometrial hyperplasia and the risk of coexistent cancer: WHO versus EIN criteria. Histopathology. 2019;74(5):676–87.

12. Alcazar JL, Bonilla L, Marucco J, Padilla AI, Chacon E, Manzour N, Salas G, De Placido G, Insabato L, Zullo F. Endometrial hyperplasia and the risk of coexistent cancer: WHO versus EIN criteria. Histopathology. 2019;74(5):676–87.

13. Alcazar JL, Bonilla L, Marucco J, Padilla AI, Chacon E, Manzour N, Salas G, De Placido G, Insabato L, Zullo F. Endometrial hyperplasia and the risk of coexistent cancer: WHO versus EIN criteria. Histopathology. 2019;74(5):676–87.

14. Alcazar JL, Bonilla L, Marucco J, Padilla AI, Chacon E, Manzour N, Salas G, De Placido G, Insabato L, Zullo F. Endometrial hyperplasia and the risk of coexistent cancer: WHO versus EIN criteria. Histopathology. 2019;74(5):676–87.

15. Alcazar JL, Bonilla L, Marucco J, Padilla AI, Chacon E, Manzour N, Salas G, De Placido G, Insabato L, Zullo F. Endometrial hyperplasia and the risk of coexistent cancer: WHO versus EIN criteria. Histopathology. 2019;74(5):676–87.

16. Alcazar JL, Bonilla L, Marucco J, Padilla AI, Chacon E, Manzour N, Salas G, De Placido G, Insabato L, Zullo F. Endometrial hyperplasia and the risk of coexistent cancer: WHO versus EIN criteria. Histopathology. 2019;74(5):676–87.

17. Alcazar JL, Bonilla L, Marucco J, Padilla AI, Chacon E, Manzour N, Salas G, De Placido G, Insabato L, Zullo F. Endometrial hyperplasia and the risk of coexistent cancer: WHO versus EIN criteria. Histopathology. 2019;74(5):676–87.

18. Alcazar JL, Bonilla L, Marucco J, Padilla AI, Chacon E, Manzour N, Salas G, De Placido G, Insabato L, Zullo F. Endometrial hyperplasia and the risk of coexistent cancer: WHO versus EIN criteria. Histopathology. 2019;74(5):676–87.

19. Alcazar JL, Bonilla L, Marucco J, Padilla AI, Chacon E, Manzour N, Salas G, De Placido G, Insabato L, Zullo F. Endometrial hyperplasia and the risk of coexistent cancer: WHO versus EIN criteria. Histopathology. 2019;74(5):676–87.

20. Alcazar JL, Bonilla L, Marucco J, Padilla AI, Chacon E, Manzour N, Salas G, De Placido G, Insabato L, Zullo F. Endometrial hyperplasia and the risk of coexistent cancer: WHO versus EIN criteria. Histopathology. 2019;74(5):676–87.

21. Alcazar JL, Bonilla L, Marucco J, Padilla AI, Chacon E, Manzour N, Salas G, De Placido G, Insabato L, Zullo F. Endometrial hyperplasia and the risk of coexistent cancer: WHO versus EIN criteria. Histopathology. 2019;74(5):676–87.

22. Alcazar JL, Bonilla L, Marucco J, Padilla AI, Chacon E, Manzour N, Salas G, De Placido G, Insabato L, Zullo F. Endometrial hyperplasia and the risk of coexistent cancer: WHO versus EIN criteria. Histopathology. 2019;74(5):676–87.

23. Alcazar JL, Bonilla L, Marucco J, Padilla AI, Chacon E, Manzour N, Salas G, De Placido G, Insabato L, Zullo F. Endometrial hyperplasia and the risk of coexistent cancer: WHO versus EIN criteria. Histopathology. 2019;74(5):676–87.

24. Alcazar JL, Bonilla L, Marucco J, Padilla AI, Chacon E, Manzour N, Salas G, De Placido G, Insabato L, Zullo F. Endometrial hyperplasia and the risk of coexistent cancer: WHO versus EIN criteria. Histopathology. 2019;74(5):676–87.

25. Alcazar JL, Bonilla L, Marucco J, Padilla AI, Chacon E, Manzour N, Salas G, De Placido G, Insabato L, Zullo F. Endometrial hyperplasia and the risk of coexistent cancer: WHO versus EIN criteria. Histopathology. 2019;74(5):676–87.

26. Alcazar JL, Bonilla L, Marucco J, Padilla AI, Chacon E, Manzour N, Salas G, De Placido G, Insabato L, Zullo F. Endometrial hyperplasia and the risk of coexistent cancer: WHO versus EIN criteria. Histopathology. 2019;74(5):676–87.

27. Alcazar JL, Bonilla L, Marucco J, Padilla AI, Chacon E, Manzour N, Salas G, De Placido G, Insabato L, Zullo F. Endometrial hyperplasia and the risk of coexistent cancer: WHO versus EIN criteria. Histopathology. 2019;74(5):676–87.

28. Alcazar JL, Bonilla L, Marucco J, Padilla AI, Chacon E, Manzour N, Salas G, De Placido G, Insabato L, Zullo F. Endometrial hyperplasia and the risk of coexistent cancer: WHO versus EIN criteria. Histopathology. 2019;74(5):676–87.

29. Alcazar JL, Bonilla L, Marucco J, Padilla AI, Chacon E, Manzour N, Salas G, De Placido G, Insabato L, Zullo F. Endometrial hyperplasia and the risk of coexistent cancer: WHO versus EIN criteria. Histopathology. 2019;74(5):676–87.

30. Alcazar JL, Bonilla L, Marucco J, Padilla AI, Chacon E, Manzour N, Salas G, De Placido G, Insabato L, Zullo F. Endometrial hyperplasia and the risk of coexistent cancer: WHO versus EIN criteria. Histopathology. 2019;74(5):676–87.
with endometrial atypical hyperplasia and endometrial cancer. Gynecol Oncol. 2019;153(1):55–62.

33. Ceylan Y, Akpinar G, Doger E, Kasap M, Guzel N, Karaosmanoglu K, Kopuk SY, Yuceso Y. Proteomic analysis in endometrial cancer and endometrial hyperplasia tissues by 2D-DIGE technique. J Gynecol Obstet Hum Reprod. 2020;49(2):101652.

34. Travaglino A, Raffone A, Saccone G, Mollo A, De Placido G, Mascolo M, Insabato L, Zullo F. Complexity of glandular architecture should be reconsidered in the classification and management of endometrial hyperplasia. APMIS. 2019;127(6):427–34.

35. Hahn HS, Chun YK, Kwon YI, Kim TJ, Lee KH, Shim JU, Mok JE, Lim KT. Concurrent endometrial carcinoma following hysterectomy for atypical endometrial hyperplasia. Eur J Obstet Gynecol Reprod Biol. 2010;150(1):80–3.

36. Man GCW, Wang J, Song Y, Wong JH, Zhao Y, Lau TS, Leung KT, Chan TH, Wang H, Kwong J, et al. Therapeutic potential of a novel prodrug of green tea extract in induction of apoptosis via ERK/JNK and Akt signaling pathway in human endometrial cancer. BMC Cancer. 2020;20(1):1964.

37. Zhang G, Chen H, Liu Y, Niu L, Jin L, Li D, Song L, Shang L, Lin X, Wang F, et al. Is lymph node dissection mandatory among early stage endometrial cancer patients? A retrospective study. BMC Womens Health. 2020;20(1):258.

38. Raffone A, Travaglino A, Saccone G, D’Alessandro P, Arduino B, Mascolo M, De Placido G, Insabato L, Zullo F. Diabetes mellitus is associated with occult cancer in endometrial hyperplasia. Pathol Oncol Res. 2020;26(3):1377–84.

39. Travaglino A, Raffone A, Saccone G, D’Alessandro P, Arduino B, De Placido G, Mascolo M, Insabato L, Zullo F. Significant risk of occult cancer in complex non-atypical endometrial hyperplasia. Arch Gynecol Obstet. 2019;300(5):1147–54.

40. Raffone A, Travaglino A, Saccone G, De Maio A, Mollo A, Mascolo M, De Rosa R, De Placido G, Insabato L, Zullo F. Diabetes mellitus and responsiveness of endometrial hyperplasia and early endometrial cancer to conservative treatment. Gynecol Endocrinol. 2019;35(1):932–7.

41. Garzon S, Uccella S, Zorzato FC, Bosco M, Franchi MP, Student V, Mariani A. Fertility-sparing management for endometrial cancer: review of the literature. Minerva Med. 2021;112(1):55–69.

42. Dashti SG, English DR, Simpson JA, Karahalios A, Moreno-Betancur M, Blessy C, Rinaldi S, Ferrari P, Tjonneland A, Halkjaer J, et al. Adiposity and endometrial cancer risk in postmenopausal women: a sequential causal mediation analysis. Cancer Epidemiol Biomark Prev. 2021;30(1):104–13.

43. Hamilton CA, Rothburn B, Arend RC, Backes FJ, Gehrig PA, Soliman PT, Thompson JS, Urban RR, Burke WM. Endometrial cancer: a society of gynecologic oncology evidence-based review and recommendations, part II. Gynecol Oncol. 2021;160(3):827–34.

44. Cordeiro Mitchell CN, Hunkler KF, Maher JY, Garbose RA, Gornet ME, Whiting-Collins L, Christianson MS. Conservatively treated endometrial intraepithelial neoplasia/cancer: risk of intrauterine synechiae. J Gynecol Obstet Hum Reprod. 2021;50(5):101930.

45. Raffone A, Travaglino A, Saccone G, Cieri M, Mascolo M, Mollo A, Insabato L, Zullo F. Diagnostic and prognostic value of ARID1A in endometrial hyperplasia: a novel marker of occult cancer. APMIS. 2019;127(9):597–606.

46. Raffone A, Travaglino A, Saccone G, Viggiani M, Giampaolino P, Insabato L, Mollo A, De Placido G, Zullo F. PTEN expression in endometrial hyperplasia and risk of cancer: a systematic review and meta-analysis. Arch Gynecol Obstet. 2019;299(6):1511–24.

47. Guleria S, Jensen A, Alberi V, Nohr B, Frederiksen K, Kjaer SK. Endometrial cancer risk after fertility treatment: a population-based cohort study. Cancer Causes Control. 2021;32(2):181–8.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.